Durability of the deltamethrin-treated polypropylene long-lasting net LifeNet® in a pyrethroid resistance area in south western Benin : a phase III trial

2023

Article référencé dans le Web of Science WOS:001088222800043

Djènontin A., Alfa D., Bouraima A., Soares C., Dahounto A., Cornélie Sylvie, Egrot Marc, Damien G., Remoué Franck, Sagna A. B., Moiroux Nicolas, Pennetier Cédric

PLoS One, 2023, 18 (9), p. e0291755 [16 p.] ISSN 1932-6203

Background Long-lasting insecticidal bed nets (LLINs) are a key measure for preventing malaria and their evaluation is coordinated by the World Health Organization Pesticide Evaluation Scheme (WHOPES). LifeNet((R)) was granted WHOPES time-limited interim recommendation in 2011 after successful Phase I and Phase II evaluations. Here, we evaluated the durability and community acceptance of LifeNet((R)) in a Phase III trial from June 2014 to June 2017 in Benin rural area. Methods A prospective longitudinal, cluster-randomized, controlled trial with households as the unit of observation was designed to assess the performance of LifeNet (R) over a three-year period, using a WHOPES fully recommended LLIN (PermaNet((R)) 2.0) as a positive control. The primary outcomes were the bioassay performance using WHO cone assays and tunnel tests, the insecticide content and physical integrity. Results At baseline, 100% of LLINs were within the tolerance limits of their target deltamethrin concentrations. By 36 months only 17.3% of LifeNet((R)) and 8.5% of PermaNet((R)) LLINs still were within their target deltamethrin concentrations. Despite these low rates, 100% of both LLINs meet WHO efficacy criteria (>= 80% mortality or >= 95% knockdown or tunnel test criteria of >= 80% mortality or >= 90% blood-feeding inhibition) after 36 months using WHO cone bio-assays and tunnel tests. The proportion of LLINs in good physical condition was 33% for LifeNet((R)) and 29% for PermaNet((R)) after 36 months. After 36 M the survivorship was 21% and 26% for LifeNet (R) and PermaNet (R) respectively. Although both LLINs were well accepted by the population, complaints of side effects were significantly higher among LifeNet((R)) users than PermaNet((R)) ones. Conclusion LifeNet((R)) LLINs did meet WHO criteria for bio-efficacy throughout the study period and were well accepted by the population. This is an important step towards getting a full WHO recommendation for use in malaria endemic countries.

Santé : généralités [050]

BENIN

Fonds IRD [F B010088673]

fdi:010088673